Christiansen Frederikke Eichner, Pedersen Torben Brøchner, Juel Jacob, Kirkeby Hans Jørgen
a Department of Urology , Aarhus University Hospital , Aarhus , Denmark.
Scand J Urol. 2017 Oct;51(5):392-396. doi: 10.1080/21681805.2017.1329228. Epub 2017 Jul 12.
This study aimed to evaluate the efficacy of treatment for incontinence due to neurogenic detrusor overactivity (NDO) and idiopathic detrusor overactivity (IDO) with onabotulinumtoxinA (BoNT-A) at Aarhus University Hospital, Skejby, Denmark.
The data were collected retrospectively by systematic review of the patient records from March 2003 to May 2012. Patients treated with BoNT-A over the age of 18 years were included. Treatment indication, diagnosis, adverse events, treatment interval, duration of effect and effect grade were registered. Follow-up data were collected by a telephone interview 4 weeks after treatment.
The study identified 219 patients, who received a total of 657 treatments during the period. Full effect of the treatment was experienced in 71%, intermediate effect was seen in 16% and low effect in 3%. There was no difference in effect duration between the IDO and NDO groups. The most common adverse event was the need to perform clean intermittent self-catheterization; 27% of all patients experienced this. Urinary tract infections were reported in 5% of procedures and significant haematuria in 1%. These findings correspond with the results of other published studies.
BoNT-A is a safe and effective treatment for incontinence in IDO and NDO.
本研究旨在评估丹麦奥胡斯大学医院斯凯比分院使用A型肉毒毒素（BoNT - A）治疗神经源性逼尿肌过度活动症（NDO）和特发性逼尿肌过度活动症（IDO）所致尿失禁的疗效。
通过系统回顾2003年3月至2012年5月的患者记录进行回顾性数据收集。纳入18岁以上接受BoNT - A治疗的患者。记录治疗指征、诊断、不良事件、治疗间隔、疗效持续时间和疗效等级。治疗后4周通过电话访谈收集随访数据。
该研究共纳入219例患者，在此期间共接受了657次治疗。71%的患者治疗效果完全显著，16%的患者效果中等，3%的患者效果不佳。IDO组和NDO组在疗效持续时间上无差异。最常见的不良事件是需要进行间歇性清洁导尿，所有患者中有27%出现此情况。5%的治疗过程报告有尿路感染，1%有明显血尿。这些结果与其他已发表研究的结果一致。
BoNT - A是治疗IDO和NDO所致尿失禁的一种安全有效的方法。
